According to The Insight Partners market research study titled ‘Epigenetics Market to 2025 - Global Analysis and Forecasts by Product, Technology, Application and End User. T
According to The Insight Partners market research study titled ‘Epigenetics Market to 2025 - Global Analysis and Forecasts by Product, Technology, Application and End User. The global epigenetics market is expected to reach US$ 2,611.57 Mn in 2025 from US$ 991.45 in 2017. The market is estimated to grow with a CAGR of 13.6% from 2018-2025. The report highlights the trends prevalent in the global epigenetics market and the factors driving the market along with those that act as deterrents to its growth.
The study of heritable changes in gene expression that do not involve changes to the underlying DNA sequence is known as epigenetics. A single or multiple change in phenotype without a changing the genotype which results affects the cells that can read the genes. The growth of the Epigenetics in healthcare market is attributed to the declining prices of sequencing, increasing prevalence of cancer and funds & grants provided by government bodies. Whereas, promising precise treatments by neurogenetics is likely to have a positive impact on the growth of the market in the coming years.
Get sample PDF Copy of Epigenetics Market Study at: https://www.theinsightpartners.com/sample/TIPHE100000971/
Epigenetics Market Competitive Landscape and Key Development
The major players operating in the epigenetics market are Merck KGaA, Thermo Fisher Scientific Inc., ABCAM Plc, Agilent Technologies, Active Motif, Qiagen, Bio-Rad Laboratories, Inc., Perkinelmer Inc., New England Biolabs (NEB), and Illumina Inc. For instance, in February, 2018, QIAGEN launches epigenetic breast cancer test in Europe. It is the first clinically validated DNA methylation assay that helps predict the response to anthracycline-based chemo by certain high-risk breast cancer patients.
The COVID-19 crisis has overburdened public health systems in many countries and highlighted the strong need for sustainable investment in health systems. As the COVID-19 pandemic progresses, the healthcare industry is expected to see a drop in growth. The life sciences segment thrives due to increased demand for invitro diagnostic products and rising research and development activities worldwide. However, the medical technologies and imaging segment is witnessing drop in sales due to a smaller number of surgeries being carried out and delayed or prolonged equipment procurement. Additionally, virtual consultations by healthcare professionals are expected to become the mainstream care delivery model post-pandemic. With telehealth transforming care delivery, digital health will continue to thrive in coming years. In addition, disrupted clinical trials and the subsequent delay in drug launches is also expected to pave the way for entirely virtual trials in the future. New technologies such as mRNA is expected to emerge and shift the pharmaceutical industry and market is also expected to witness more vertical integration and joint ventures in coming years.
Growing Applications of Epigenetics in Healthcare to Drive Epigenetics in Healthcare Market Growth
The declining costs associated with different strategies and methods for sequencing supports to influence the scale and scope of almost all genomic research projects. The costs associated with DNA sequencing performed at the sequencing centers which is funded by the Institutes, has tracked by the National Human Genome Research Institute (NHGRI) for many years. This information has served as a key standard for establishing the DNA sequencing capacity and considering improvements in DNA sequencing technologies of the NHGRI Genome Sequencing Program (GSP).
In the recent years, next generation sequencing price have declined substantially. For instance, first whole human genome sequencing cost over US$3.7 billion in 2000 and took 13 years for the completion. However, the costs for the same in recent years has reduces to US$1,000 and the process requires less number of days. In 2000, cost for sequencing was US$ 3.7 billion, which dropped down to US$ 10 million in 2006 and declined to US$ 5,000 in 2012. Major market players such as Illumina and Roche have introduced breakthrough technologies that have enabled in the cost and time reduction in the sequencing.
In recent years, the cases of cancer has been increasing tremendously and the trend is anticipated to remain the same in the upcoming years. Changes in lifestyle has resulted in more exposure to oncogenic factors. For instance, the American Cancer Society estimated 1,658,370 cancer cases to be detected in the US in 2015. Cancer can be cured if diagnosed and treated at an initial stage. Cancer sequencing using next-generation sequencing (NGS) methods provides more information. Additionally, epigenetics also aids in research, diagnostics and treatment of cancer.
The National Science Foundation (NSF) proposed a program named “Understanding the Rules of Life: Epigenetics” which is going be launched in 1 February 2019. In 2016, the National Science Foundation (NSF) showed a set of “Big Ideas,” 10 bold, long-term research and process ideas that classify the areas for future investment at the frontiers of science & engineering. The purpose of the program is to allow the innovative researches to promote multidisciplinary education and workforce training in the broad area of epigenetics. The development of new research tools has developed to investigate the genome and to measure multiple aspects of physical, biological and social environments.
Epigenetics Market: Segmental Overview
Based on technology, the Epigenetics in healthcare market is segmented into histone modification, dna methylation and others. In 2017, the DNA methylation segment held a largest market share of 51.1% of the epigenetics market, by technology. This segment is also expected to dominate the market in 2025 as the technology mechanistic change in genomic conformation sets out a platform for various cellular processes, such as the exposure of the promoter of a specific gene to its transcriptional machinery.
In terms of product, the Epigenetics in healthcare market is segmented into reagents, kits, enzymes, instruments & consumables and bioinformatics tools. In 2017, the kits segment held a largest market share of 29.8% of the epigenetics market, by product. This segment is also expected to dominate the market in 2025 owing to availability of several kits in the market for the gene expression analysis such as MicroRNA analysis, SNP genotyping analysis and other procedures.
Buy Complete Report of Epigenetics Market Study at: https://www.theinsightpartners.com/buy/TIPHE100000971/
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
E-mail: sales@theinsightpartners.com